NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Wall Street major averages posted weekly loses amid an AI-tech trade that continued to struggle, with lower consumer ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Pfizer (PFE) wins Metsera (MTSR) buyout after a heated bidding war with Novo Nordisk (NVO), securing a $10B deal for the ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's merger agreement and seeks to bypass antitrust review ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a smaller competitor.